| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Verrica Pharmaceuticals Inc.$6.26
-0.27 (-4.13%)
F 15Pipeline Score Richly Valued Pharma · Commercial
Market Cap
104.10 M
EPS
-1.03
P/E Ratio
-
Value Trade
144.14 K
SEC Financials
Q1 2026Dilution Risk
Revenue
5.02 M
R&D Expenses
3.86 M
Operating CF
-9.16 M
Total Assets
38.79 M
Total Liabilities
22.73 M
Equity
16.05 M
D/E Ratio
12,345
-11.53 %
Week
-6.05 %
1 Month
-2.26 %
3 Month
48.17 %
6 Month
-94.68 %
5 Year
-96.97 %
All Time
Cash Data
Cash Position
20.60 M
Monthly Burn
3.05 M
Runway
5 mo
Burn Trend
SEC Filing
May 12, 2026
Overview
Volume
14.05 K
52 Week Range
3.28 - 9.82
% held by Insiders
48.75 %
% held by Institutions
27.81 %
Enterprise Value
84.95 M
Total Shares
15.99 M
Short %
5.77 %
Float Shares
5.63 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Verrica Pharmaceuticals Inc.
379Total events
4Upcoming
109Tier-1 (high impact)
2018 – 2027Coverage
Upcoming catalysts 4
TBD
T3Manufacturing Milestone
Manufacturing transfer to Torii for YCANTH applicators expected to take several years
Event history 375
Jun 22, 2026
▲First Patient DosedVP-102 / TO-208ApprovedTrial
First U.S. patient dosed in COVE-3 trial
common wartssource ↗
Jun 4, 2026
Jun 2026
▲First Patient DosedVP-102 / TO-208ApprovedTrial
First Japanese patient dosed in COVE-3 trial
common wartssource ↗
May 19, 2026
◆Oral PresentationPresentation
Verrica to present at H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
May 15, 2026
◆Poster PresentationVP-315Presentation
Poster presentation of VP-315 Phase 2 data at 2026 SID Annual Meeting
basal cell carcinomasource ↗
May 15, 2026
◆Late-BreakerVP-315Presentation
Late-breaking abstract accepted for VP-315 abscopal effect data at SID 2026
basal cell carcinomasource ↗
May 12, 2026
◆Quarterly UpdateCorporate
First Quarter 2026 Financial Results and Corporate Update Conference Call
May 12, 2026
▲Enrollment MilestoneVP-102 / TO-208ApprovedTrial
Achieved over 50% of current targeted enrollment in COVE-2 trial
common wartssource ↗
May 2026
▲Enrollment UpdateVP-102 / TO-208ApprovedTrial
Over 50% of targeted enrollment achieved in COVE-2
common wartssource ↗
May 2026
●Trial InitiationVP-102 / TO-208ApprovedTrial
Long-term follow-up study COVE-4 enrolling U.S. patients
common wartssource ↗
Apr 15, 2026
◆Oral PresentationPresentation
Verrica to present at 25th Annual Needham Virtual Healthcare Conference
Apr 9, 2026
▲AbstractVP-315Presentation
Late-breaking abstract accepted for VP-315 Phase 2 exploratory data in BCC at SID 2026
basal cell carcinomasource ↗
Drug Pipeline Intelligence
F15
Pipeline Score $7M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 11%
Micro Cap (rank 812 of 911)
Percentile RankVerrica Pharmaceuticals Inc. has significant pipeline risk (15/100), with $201M risk-adjusted pipeline value, led by Part 1: VP-315 3 Day Dosing/Week in Basal Cell Carcinoma (Phase 2), but cash runway is a concern.
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Part 1: VP-315 3 Day Dosing/Week Small molecule | Basal Cell Carcinoma | Phase 2 | NCT05188729 | 10% | $201M | COMPLETED | 92 | - | - | Apr 15, 2024 | - | Jun 18, 2025 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
VP-315 | Basal Cell Carcinoma | Phase 2 | 2026-05-06 | overall tumor size was reduced on average by 86% | Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting Read More | |
VP-315 | Basal Cell Carcinoma | Phase 2 | 2026-05-06 | overall tumor size was reduced on average by 86% | Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting Read More | |
VP-315 | Basal Cell Carcinoma | Phase 2 | 2026-05-06 | overall tumor size was reduced on average by 86% | Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in VRCA
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
VRCA Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
VRCAVerrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
Verrica Pharmaceuticals has announced the dosing of the first U.S. patient in the COVE-3 pivotal clinical trial for YCANTH (VP-102), aimed at treating common warts. This trial is part of a global Phase 3 program, which also includes a Japanese trial with Torii Pharmaceutical. The company aims to address the significant unmet need in dermatology, with common warts affecting millions annually.
Read more →VRCAVerrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference
Verrica Pharmaceuticals Inc. will present at the Jefferies Global Healthcare Conference on June 4, 2026. CEO Jayson Rieger will discuss the company's advancements in dermatological therapeutics, including their FDA-approved treatment for molluscum contagiosum. The event will be accessible via a live webcast, with a replay available for 90 days.
Read more →VRCAVerrica Pharmaceuticals Reports First Quarter 2026 Financial Results
Verrica Pharmaceuticals reported strong financial results for Q1 2026, with significant growth in demand for its product YCANTH, which saw a 12.1% increase in dispensed units from the previous quarter. The company also achieved over 50% enrollment in its Phase 3 trial for common warts and expanded its market presence with a launch in Japan. Total revenue reached $5.0 million, reflecting a positive trend in the company's performance.
Read more →VRCAVerrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Verrica Pharmaceuticals will present at the H.C. Wainwright 4th Annual BioConnect Investor Conference on May 19, 2026. CEO Jayson Rieger will discuss the company's advancements in dermatological therapeutics, including its FDA-approved treatment for molluscum contagiosum. The event will be accessible via a live webcast and will be available for replay afterward.
Read more →VRCA▲ +17.7%on this news
Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting
Verrica Pharmaceuticals announced the presentation of Phase 2 data on VP-315, highlighting its potential abscopal effects in treating basal cell carcinoma. The data, to be presented at the 2026 SID Annual Meeting, showed significant tumor size reduction in untreated lesions. The findings suggest VP-315 could offer a non-surgical option for patients with multiple tumors.
Read more →VRCA▲ +12.6%on this news· ran to +33% by day 1shared move
Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026
Verrica Pharmaceuticals Inc. will host a conference call on May 12, 2026, to discuss its first quarter financial results and provide a corporate update. The call will be accessible via telephone and a live audio webcast. Verrica is known for its FDA-approved treatment for molluscum contagiosum and is developing additional therapies for skin cancers.
Read more →VRCA▼ -12.3%on this news
Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting
Verrica Pharmaceuticals announced the acceptance of a late-breaking abstract for VP-315, an oncolytic peptide, at the 2026 Society for Investigative Dermatology Annual Meeting. The abstract highlights Phase 2 exploratory data suggesting a potential abscopal effect in treating basal cell carcinoma. This presentation underscores the importance of VP-315 as a promising non-surgical option for patients.
Read more →VRCA▲ +9.3%on this newsshared move
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
Verrica Pharmaceuticals will present at the 25th Annual Needham Virtual Healthcare Conference on April 15, 2026. CEO Jayson Rieger will discuss the company's advancements in dermatological therapeutics, including their FDA-approved treatment for molluscum contagiosum. The event will be accessible via a live webcast, with a replay available for 90 days post-event.
Read more →VRCAVerrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - YCANTH net revenue grew 130% to $15.3 million in 2025, and selling, general and administrative expenses decreased by over 40%, when co
Verrica Pharmaceuticals reported significant financial growth in 2025, with YCANTH net revenue increasing by 130% to $15.3 million. The company experienced a substantial rise in applicator unit sales and successfully reduced operating expenses. Advancements in their clinical pipeline include the initiation of a Phase 3 study for YCANTH and ongoing development of VP-315 for basal cell carcinoma. Moreover, Verrica gained regulatory alignment for YCANTH's approval process in the EU, enhancing its strategic outlook and partnerships.
Read more →VRCAVerrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026
Verrica Pharmaceuticals Inc. will hold a conference call on March 11, 2026, to report its financial results for the fourth quarter and full year of 2025. The call will provide updates on the company's performance and ongoing developments in dermatology therapeutics. Notably, Verrica's product YCANTH® is the first FDA-approved treatment for molluscum contagiosum.
Read more →VRCAVerrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference
Verrica Pharmaceuticals Inc. will present at the TD Cowen 46th Annual Health Care Conference in Boston on March 2, 2026. CEO Jayson Rieger will lead the presentation, which can be accessed via a live webcast. The company is known for its FDA-approved treatment for molluscum contagiosum and is developing additional dermatological therapies.
Read more →VRCAVerrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
Verrica Pharmaceuticals has appointed Chris Chapman as Chief Commercial Officer. With over 25 years of experience, Chapman aims to enhance the commercial success of YCANTH, a treatment for molluscum contagiosum, and support the development of VP-315 for basal cell carcinoma. His leadership is expected to broaden access to these therapies.
Read more →VRCAVerrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical
Verrica Pharmaceuticals has announced the launch of YCANTH® in Japan by its partner, Torii Pharmaceutical, for treating molluscum contagiosum. This launch follows the approval from the Japanese Ministry of Health, based on positive Phase 3 trial results. The product aims to fill a significant treatment gap in Japan, where few options are currently available.
Read more →VRCAVerrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts
Verrica Pharmaceuticals has initiated the global Phase 3 program for YCANTH (VP-102) targeting common warts, marking a significant milestone in its label expansion strategy. The first patient was dosed in December 2025, following promising Phase 2 results that indicated a 51% complete clearance rate. With no FDA-approved therapies for common warts, the company sees a substantial commercial opportunity in this market.
Read more →VRCA▲ +12.1%on this news· ran to +116% by day 3
Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway
Verrica Pharmaceuticals announced a $50 million PIPE financing to eliminate its debt and extend its cash runway into mid-2027. This funding will support the advancement of its commercial strategy for YCANTH and the development of VP-315 for basal cell carcinoma. The financing is set to close around November 25, 2025, pending customary conditions.
Read more →VRCA▼ -5.1%on this news
Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results - Company reports $14.3 million in revenue in Q3'25, consisting of $3.6 million in YCANTH revenue and $10.7 million of license and collaboration revenu
Verrica Pharmaceuticals announced its financial results for Q3 2025, highlighting $14.3 million in revenue, driven mainly by YCANTH and licensing collaborations. The company received positive regulatory feedback from both the FDA and EMA regarding its drug candidates, particularly for YCANTH and VP-315. Significant increases in the dispensed units of YCANTH indicate strong market uptake. Verrica is well-positioned for future growth, supported by advancements in its clinical pipeline and upcoming milestones.
Read more →VRCAVerrica Pharmaceuticals Reports Third Quarter 2025 Financial Results
Verrica Pharmaceuticals reported its financial results for the third quarter of 2025, achieving $14.3 million in revenue. The company secured positive regulatory feedback from both the FDA and the European Medicines Agency, facilitating advancements for its products VP-315 and YCANTH. Additionally, a milestone payment of $10 million was received due to YCANTH's approval in Japan. The company's sales force is expanding, and they are progressing with clinical trials, positioning Verrica for future growth in the dermatology sector.
Read more →VRCA▲ +11.8%on this news
Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting
Verrica Pharmaceuticals presented new data on VP-315, an oncolytic peptide, at the SITC Annual Meeting. The Phase 2 study showed a 97% objective response rate and a 51% complete histologic clearance rate in basal cell carcinoma patients. The findings support VP-315's potential as a first-in-class immunotherapy, with a favorable safety profile. The company is preparing for a pivotal Phase 3 program following positive FDA feedback.
Read more →VRCA▼ -9.8%on this news
Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH® in the European Union
Verrica Pharmaceuticals has received positive feedback from the EMA regarding its product YCANTH for the treatment of molluscum contagiosum. The EMA concluded that existing Phase 3 study data is sufficient for a Marketing Authorization Application (MAA) in the EU, with no further studies needed. The company plans to submit the application as early as Q4 2026, addressing a significant unmet need in the European market.
Read more →VRCAVerrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
Verrica Pharmaceuticals Inc. has announced that it will present new data on VP-315, an investigational therapy for basal cell carcinoma (BCC), at the upcoming Society for Immunotherapy of Cancer (SITC) Annual Meeting in November 2025. This phase 2 trial explores the local immune activation in BCC patients post-treatment. VP-315 is being developed as a potential first-in-class option for patients with skin cancers, leveraging innovative oncolytic peptide therapy that may induce immunogenic cell death. The data presentation includes both an oral and a poster presentation led by prominent researchers in the field.
Read more →VRCA▲ +8.7%on this news
Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH® (TO-208) in Japan for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals announced that its partner, Torii Pharmaceutical, has received approval for YCANTH (TO-208) in Japan for treating molluscum contagiosum. This approval triggers a $10 million milestone payment to Verrica, enhancing its financial position. The company aims to establish YCANTH as the standard of care and is exploring further global approvals.
Read more →VRCAVerrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Verrica Pharmaceuticals announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 8-10, 2025. CEO Jayson Rieger will present at the event in New York City. The company is known for its dermatology therapeutics, including the FDA-approved YCANTH® for molluscum contagiosum and ongoing developments for other skin conditions.
Read more →VRCAVerrica Pharmaceuticals Reports Second Quarter 2025 Financial Results
Verrica Pharmaceuticals reported $12.7 million in revenue for Q2 2025, driven by significant growth in YCANTH sales and milestone revenue from Torii Pharmaceutical. The company successfully completed an End of Phase 2 meeting for VP-315, preparing for a Phase 3 program. They are also exploring non-dilutive financing options to support further development.
Read more →VRCA▲ +9.2%on this news· ran to +20% by day 3
Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025
Verrica Pharmaceuticals Inc. announced that it will host a conference call on August 12, 2025, to discuss its financial results for the second quarter of 2025 and provide a corporate update. The call will be accessible to participants by telephone and through a live webcast on the company's website. Verrica is known for its YCANTH® (VP-102) product, FDA-approved for treating molluscum contagiosum, as well as its partnership with Lytix Biopharma to develop VP-315 for non-melanoma skin cancers.
Read more →VRCAVerrica Pharmaceuticals Reports Strong Growth in YCANTH® Dispensed Applicator Units in 2Q 2025
Verrica Pharmaceuticals reported a significant 32.8% growth in dispensed YCANTH applicator units in Q2 2025, totaling 13,434 units. The company also received an $8 million milestone payment from Torii Pharmaceutical for the initiation of a global Phase 3 program targeting common warts. CEO Jayson Rieger highlighted the success of their commercial strategy and patient access initiatives.
Read more →VRCA▲ +13.4%on this news· ran to +57% by day 3
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
Verrica Pharmaceuticals has amended its collaboration agreement with Torii Pharmaceutical to initiate a global Phase 3 clinical trial for YCANTH® targeting common warts. The company will receive an $8 million milestone payment and anticipates a $10 million payment upon approval for molluscum contagiosum in Japan. The trial aims to address a significant unmet need in dermatology, with the first patient expected to be dosed in late 2025.
Read more →VRCA▼ -5.8%on this news
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York
Verrica Pharmaceuticals will present at the Jefferies Global Healthcare Conference on June 4, 2025. CEO Jayson Rieger will discuss the company's advancements in dermatology therapeutics, including their FDA-approved treatment YCANTH® for molluscum contagiosum. The event will be accessible via a live webcast, with a replay available for 90 days post-presentation.
Read more →VRCA▲ +8.6%on this news· ran to +31% by day 3
Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results Company reports $3.4 million in YCANTH revenue, reflective of increasing demand, following the dispensing of more than 10,000 applicator units in the quart
Verrica Pharmaceuticals has reported its financial results for Q1 2025, announcing $3.4 million in revenue from its product YCANTH, which reflects a strong demand increase. The company has dispensed over 10,000 applicator units during this quarter, marking a significant milestone. Additionally, Verrica is advancing its clinical pipeline, including the initiation of a global Phase 3 program for common warts in partnership with Torii Pharmaceutical and the development of an oncolytic peptide, VP-315, for basal cell carcinoma.
Read more →VRCA▼ -9.2%on this news
Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025
Verrica Pharmaceuticals Inc. announced a conference call and webcast scheduled for May 13, 2025, to discuss its first-quarter financial results and provide a corporate update. The company specializes in developing dermatology treatments, notably for conditions like molluscum contagiosum. Its product, YCANTH® (VP-102), is the only FDA-approved treatment for this skin infection. Verrica is also collaborating with Lytix Biopharma on another skin cancer treatment.
Read more →VRCAVerrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York
Verrica Pharmaceuticals announced that its CEO, Jayson Rieger, will present at the Citizens Life Sciences Conference in New York City on May 7, 2025. This event will highlight Verrica's innovative approach to dermatological treatments, particularly their FDA-approved product YCANTH for treating molluscum contagiosum. The conference is a platform for sharing advancements in life sciences and may further position Verrica in the dermatology market. A live webcast of the event will be available for interested investors and stakeholders.
Read more →VRCA▲ +21.8%on this news
Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH Dispensed Applicator Units in First Quarter 2025
Verrica Pharmaceuticals reported significant growth in demand for its YCANTH dispensed applicator units, surpassing 10,000 units in the first quarter of 2025. This marks a sequential increase of 16.7% from the previous quarter, reflecting a successful commercial restructuring and enhanced market access. The company expects that normalized distributor inventory levels will help align dispensed units with demand, potentially driving revenue growth. CEO Jayson Rieger expressed optimism about establishing YCANTH as the standard treatment for molluscum contagiosum moving forward.
Read more →VRCAVerrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors
Verrica Pharmaceuticals has appointed Dr. Gavin Corcoran to its Board of Directors to support the growth of its commercial business and late-stage pipeline. Dr. Corcoran brings extensive experience from previous roles in pharmaceutical development and is expected to provide valuable insights as Verrica expands its innovative dermatological products. The appointment aligns with the growing adoption of Verrica's drug YCANTH®, approved for treating molluscum contagiosum, a highly contagious skin condition affecting many children.
Read more →VRCAVerrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference
Verrica Pharmaceuticals Inc. announced its participation in the 24th Annual Needham Virtual Healthcare Conference, scheduled for April 8, 2025. CEO Dr. Jayson Rieger will take part in a fireside chat during the event, which showcases the company's advancement in dermatology therapeutics. The webcast can be accessed live and will also be available for replay afterwards. Verrica continues to develop innovative medications for skin diseases, including its FDA-approved YCANTH® for molluscum contagiosum.
Read more →VRCA▼ -6.8%on this newsshared move
Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
Verrica Pharmaceuticals has appointed Dr. Noah L. Rosenberg as its new Chief Medical Officer. Dr. Rosenberg brings over 30 years of experience in drug development, which is expected to assist Verrica in enhancing its clinical programs, particularly for its product YCANTH aimed at treating molluscum contagiosum. He expressed enthusiasm about the opportunity to develop new treatments for prevalent skin conditions. This leadership change follows the previous CMO Gary Goldenberg's contributions, including approval of YCANTH.
Read more →VRCAVerrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results Company generated quarterly sequential growth in YCANTH dispensed applicator units of 12.3% in Q4 24 concurrent with significantly lower
Verrica Pharmaceuticals reported positive financial results for Q4 2024, showing a 12.3% sequential growth in YCANTH applicator units. The company also noted reduced operating expenses and a stronger balance sheet due to a recent public offering. The CEO emphasized their focus on establishing YCANTH as the standard treatment for molluscum contagiosum while advancing clinical programs for basal cell carcinoma and common warts. A conference call is scheduled to discuss these results in detail.
Read more →VRCAVerrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025
Verrica Pharmaceuticals Inc. will host a conference call on March 11, 2025, to discuss its financial results for the fourth quarter and full year of 2024. The call will provide insights into the company's performance and a corporate update. Verrica is known for developing treatments for skin diseases, including the recently FDA-approved YCANTH for molluscum contagiosum. The company is also pursuing additional therapies for common warts and non-melanoma skin cancers.
Read more →VRCAVerrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston
Verrica Pharmaceuticals Inc. will participate in the TD Cowen 45th Annual Health Care Conference in Boston from March 3-5, 2025. CEO Jayson Rieger will engage in a fireside chat, offering insights into the company's initiatives. Verrica focuses on developing dermatology treatments, including its FDA-approved product YCANTH for molluscum contagiosum. The event allows investors to access a live webcast and a replay post-event, furthering engagement with the company's developments.
Read more →VRCA▲ +5.1%on this news
Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference
Verrica Pharmaceuticals presented three posters at the 2025 Winter Clinical Dermatology Conference showcasing positive preliminary results for VP-315, an investigational treatment for basal cell carcinoma (BCC). The posters revealed a 97% calculated objective response rate, highlighting both safety and tolerability data from a Phase 2 study involving 92 patients. Verrica plans to discuss the next steps with the FDA and aims to position VP-315 as a non-surgical alternative for BCC treatment, targeting a significant commercial opportunity.
Read more →VRCAVerrica Provides Business and Operational Update
Verrica Pharmaceuticals Inc. provided a business and operational update indicating progress in their commercial strategy for YCANTH, aimed at treating molluscum contagiosum. They reported stronger demand, with dispensed applicator units in Q4 surpassing the previous quarter, and a significant reduction in inventoried stock. Furthermore, a new single applicator configuration for YCANTH is anticipated for release in Q1 2025, enhancing physician access and potentially increasing patient availability. The company is also advancing its product pipeline targeting common warts and basal cell carcinoma.
Read more →VRCA▼ -5.9%on this news· ran to -21% by day 3
Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Verrica Pharmaceuticals announced the grant of a stock option to new Chief Operating Officer David Zawitz under its Inducement Plan. This grant covers 950,000 shares of common stock, intended to incentivize Zawitz's employment in alignment with Nasdaq Listing Rule 5635(c)(4). The option will have a standard vesting schedule, rewarding long-term commitment. Verrica's focus on dermatology therapeutics includes ongoing development of treatments for various skin conditions.
Read more →VRCAVerrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan
Verrica Pharmaceuticals announced that its partner, Torii Pharmaceutical, has submitted a New Drug Application for TO-208, aimed at treating Molluscum Contagiosum in Japan. This NDA marks an important step toward providing the first therapeutic solution for this condition in the country, addressing a significant unmet need for approximately 1.6 million affected individuals. The drug has shown positive Phase 3 clinical trial results, indicating efficacy and a consistent safety profile. This development follows Verrica's earlier FDA approval of its treatment for molluscum in the U.S., as well as ongoing efforts to expand its product offerings in dermatology.
Read more →VRCA▲ +11.6%on this news· ran to +25% by day 3
Verrica Announces Pricing of $42.0 Million Public Offering
Verrica Pharmaceuticals has announced the pricing of a public offering of approximately $42 million. This offering includes nearly 45 million shares of common stock and accompanying warrants. The transaction is expected to close on November 22, 2024, contingent on customary conditions. This move is part of Verrica's strategy to fund its dermatological product development, including treatments for skin diseases.
Read more →VRCAVerrica Announces Proposed Public Offering
Verrica Pharmaceuticals has announced its intention to conduct a public offering of shares and pre-funded warrants to support its dermatology therapeutic developments. The offering is subject to market conditions and may include an option for the underwriter to purchase additional shares. The proposed financial initiative follows Verrica's effective registration statement with the SEC and highlights the continued development of its treatment for skin diseases, including FDA-approved YCANTH for molluscum contagiosum. However, uncertainties regarding market conditions and offering details introduce potential risks.
Read more →VRCA▼ -6.5%on this news· ran to -54% by day 3
Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition Company reported $0 in product shipments in the third quarter of 2024 and recognized negative net product revenue o
Verrica Pharmaceuticals has reported its financial results for the third quarter of 2024, revealing no product shipments and a negative net revenue of $1.9 million. As part of a leadership transition, Dr. Jayson Rieger has been appointed CEO, and John Kirby as Interim CFO. The company is implementing strategies to lower operating expenses and expand access to its product, YCANTH, for molluscum contagiosum. Although there is positive feedback for YCANTH, the restructuring reflects challenges that the company faces in stabilizing its financial performance.
Read more →VRCAVerrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference
Verrica Pharmaceuticals has announced the acceptance of two abstracts detailing positive preliminary results from their Phase 2 trial of VP-315 for the treatment of basal cell carcinoma. The results suggest a significant efficacy rate, with over 50% of tumors achieving complete histological clearance and a reduction in tumor size observed in patients with residual tumors. No serious treatment-related adverse events were reported, indicating favorable safety and tolerability. The company plans to present these findings at the Fall Clinical Dermatology Conference and will seek further regulatory guidance from the FDA in 2025.
Read more →VRCA▼ -19%on this news
Verrica Pharmaceuticals Announces Restructuring of Commercial Organization
Verrica Pharmaceuticals has announced a major restructuring of its commercial organization aimed at reducing costs and optimizing operational efficiency. The company's sales and marketing efforts will refocus on pediatricians to enhance access to its product, YCANTH®, traditionally used for molluscum contagiosum. This restructuring is projected to decrease overall operating expenses by about 50%, though Verrica will incur a one-time charge of $1.0 million. These changes are part of a broader strategy to establish YCANTH® as the standard treatment for this common skin condition.
Read more →VRCA▲ +5.5%on this news
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York
Verrica Pharmaceuticals Inc. announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, taking place from September 9-11, 2024, in New York City. Ted White, the company's President and CEO, will engage in a fireside chat during the event. Interested parties can access a live webcast and a recorded version will be made available for 90 days following the conference. The event reflects Verrica's ongoing efforts to enhance visibility in the dermatology sector.
Read more →VRCA▼ -40.8%on this news
Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results Reports YCANTH revenue, net of $4.9M for second quarter of 2024 along with the expansion of YCANTH s distribution footprint to include Cencora, Inc. a
Verrica Pharmaceuticals reported its second quarter 2024 financial results, revealing a net revenue of $4.9 million from its YCANTH product. The company announced positive preliminary results from its Phase 2 study of VP-315 for basal cell carcinoma and is preparing for a global Phase 3 trial for common warts anticipated to start in the first half of 2025. Despite these advancements, Verrica faces challenges with rising operating expenses and a significant net loss.
Read more →VRCA▼ -40.8%on this news
Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma
Verrica Pharmaceuticals announced positive preliminary results from Part 2 of its Phase 2 clinical trial for VP-315, an oncolytic peptide-based immunotherapy targeting basal cell carcinoma. The treatment was well tolerated, showing an overall tumor size reduction of approximately 86% across all patients, with 51% achieving complete histological clearance. The company believes the results could enhance treatment options for patients and supports VP-315 as a first-line therapy. The drug's promising performance suggests a significant potential market opportunity for Verrica.
Read more →VRCA▼ -5.5%on this news
Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024
Verrica Pharmaceuticals Inc. announced a conference call scheduled for August 14, 2024, to discuss its second quarter financial results and provide preliminary topline results from the Phase 2 trial of VP-315 for treating basal cell carcinoma. This call will showcase the company's financial transparency as well as advancements in its therapeutic pipeline. Verrica has recently gained attention for its FDA-approved treatment for molluscum contagiosum and is actively pursuing additional dermatological applications.
Read more →VRCA▲ +9.1%on this news
Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc.
Verrica Pharmaceuticals announced a litigation settlement with Dormer Laboratories, halting the sale of all cantharidin-containing products in the U.S. This settlement is seen as beneficial for increasing the use of Verrica's FDA-approved therapy, YCANTH, for molluscum contagiosum, a common skin condition. YCANTH is the first FDA-approved treatment for this condition, which primarily affects children. Verrica emphasizes its commitment to patient safety and adherence to FDA regulations, alongside ongoing development of other treatments for dermatological conditions.
Read more →VRCAVERRICA ALERT: Bragar Eagel & Squire, P.C. is Investigating Verrica Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
Bragar Eagel & Squire, P.C. is conducting an investigation on behalf of long-term stockholders of Verrica Pharmaceuticals due to potential fiduciary breaches by the board. This follows a class action complaint related to the company's New Drug Application for VP-102 for the treatment of molluscum. Verrica has faced regulatory setbacks, including multiple Complete Response Letters from the FDA that have resulted in significant drops in its stock price. The investigation focuses on allegations of materially misleading statements made by the company regarding manufacturing deficiencies and their impact on obtaining regulatory approval.
Read more →VRCAVerrica Pharmaceuticals Announces Amendment to Company s Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Wa
Verrica Pharmaceuticals has amended its collaboration agreement with Torii Pharmaceutical Co. to jointly conduct a global pivotal Phase 3 clinical trial for YCANTH, targeting the treatment of common warts. The trial is expected to begin in the first half of 2025 and represents a significant opportunity in addressing a large, unmet medical need. With approximately 22 million individuals affected in the U.S. and no FDA-approved therapies, the partnership aims to advance clinical development while strategically managing costs. Positive prior results from a Phase 2 trial further support the feasibility of this initiative.
Read more →VRCA▲ +19.5%on this newsshared move
Verrica Pharmaceuticals Reports First Quarter 2024 Financial Results Reports YCANTH revenue of $3.2M for first quarter of 2024 Over 228 million lives now covered to date on commercial insurance, managed Medicaid, Tricare
Verrica Pharmaceuticals reported its financial results for Q1 2024, showcasing a revenue of $3.2 million from YCANTH and a coverage of over 228 million lives through various insurance plans. The company highlighted positive developments, including the receipt of a permanent J-Code from CMS and anticipated Phase 2 results for their lead candidate, VP-315. However, they also noted significant losses and increased operating expenses during this period, emphasizing financial challenges they face as they progress.
Read more →VRCAVerrica Pharmaceuticals to Present at Upcoming Investor Conferences
Verrica Pharmaceuticals Inc. has announced upcoming presentations by its CEO, Ted White, at two investor conferences in New York during May 2024. The company's key focus is on developing treatments for skin diseases, highlighted by the recent FDA approval of YCANTH® for molluscum contagiosum. Additionally, Verrica is advancing its product pipeline, including treatments for common and external genital warts, as well as developing VP-315 for non-melanoma skin cancers.
Read more →VRCAVerrica Pharmaceuticals to Provide a Corporate Update and Report First Quarter 2024 Financial Results on May 13, 2024
Verrica Pharmaceuticals Inc. has announced a conference call and live webcast on May 13, 2024, to provide a corporate update and discuss its financial results for the first quarter of 2024. The company recently received FDA approval for its lead product, YCANTH™, to treat molluscum contagiosum, a contagious skin infection. Verrica continues to develop additional products for various dermatological conditions, showcasing its focus on medical interventions in dermatology.
Read more →VRCAVerrica Pharmaceuticals Announces Presentation at the 23rd Annual Needham Virtual Healthcare Conference
Verrica Pharmaceuticals Inc. will present at the 23rd Annual Needham Virtual Healthcare Conference from April 8-11, 2024. The presentation will feature insights from Ted White, the company's President & CEO, and offers investors access to a live webcast. The event comes on the heels of the FDA approval for Verrica's YCANTH treatment for molluscum contagiosum, highlighting the company's role in dermatology therapeutics.
Read more →VRCA▲ +5.1%on this news· ran to +17% by day 3
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
Verrica Pharmaceuticals announced that its lead product, YCANTH, has received New Chemical Entity status and a listing in the FDA's Orange Book, ensuring a minimum of five years of regulatory exclusivity. This move is part of Verrica's broader strategy to enhance its intellectual property protection. The company highlights that its full patent portfolio may safeguard against generic competition for up to a decade. YCANTH is already approved for treating molluscum contagiosum in patients aged two and older.
Read more →VRCA▼ -7.9%on this news
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results Reports YCANTH revenue of $1.9M for fourth quarter and $4.7M for full year 2023 Over 200 million lives now covered on commercial insuran
Verrica Pharmaceuticals has reported its financial results for Q4 and the full year of 2023, highlighting a notable revenue of $1.9 million for YCANTH in the last quarter. The company stated that over 200 million lives are now covered under commercial insurance and Medicaid plans. They have also made progress in their clinical trials, having gained FDA alignment for a Phase 3 trial for YCANTH and completed enrollment for a Phase 2 study of another product, VP-315. Despite these advancements, the company experienced significant overall financial losses in 2023 compared to the previous year.
Read more →VRCA▲ +5%on this newsshared move
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
Verrica Pharmaceuticals Inc. has announced its participation in the TD Cowen 44th Annual Healthcare Conference on March 5, 2024, in Boston, Massachusetts. The company, focused on dermatology therapeutics, will engage in a fireside chat to discuss its advancements and strategies. Recently, Verrica received FDA approval for YCANTH, a treatment for molluscum contagiosum, and is developing additional products for common warts and non-melanoma skin cancers. Live webcasts of the conference and a replay will be accessible on the company's website.
Read more →VRCAVerrica Pharmaceuticals to Provide a Corporate Update and Report Fourth Quarter and Full-Year 2023 Financial Results on February 29, 2024
Verrica Pharmaceuticals announced it will host a conference call on February 29, 2024, to provide a corporate update and discuss its financial results for the fourth quarter and full-year 2023. The company has recently achieved FDA approval for its lead product, YCANTH, used to treat molluscum contagiosum. This marks a significant advancement in its dermatological therapeutic offerings. Additionally, Verrica is working on several other therapies targeting common warts and skin cancers.
Read more →VRCA▼ -7.6%on this news
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
Verrica Pharmaceuticals has filed a lawsuit against Canadian company Dormer Laboratories for false advertising related to unapproved cantharidin-containing drugs. The legal action seeks to stop Dormer Labs from marketing these products in the U.S. and demands damages for violations of federal and state law. This lawsuit underscores Verrica's dedication to ensuring patient safety and upholding the integrity of its own FDA-approved product, YCANTH, used for treating molluscum contagiosum.
Read more →VRCAVerrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
Verrica Pharmaceuticals Inc. has received a permanent J-Code (J7354) for its FDA-approved product YCANTH™, the only treatment for molluscum contagiosum. This coding, effective April 1, 2024, is anticipated to facilitate increased utilization among Medicare and Medicaid patients, as well as improve billing and reimbursement processes. The company has also completed Phase 2 studies for its VP-102 treatment targeting common and external genital warts, indicating ongoing innovation in their dermatology portfolio.
Read more →VRCA▼ -6%on this news
Company Overview January 2024 Copyright 2024 Verrica Pharmaceuticals. All rights reserved. Not For Promotional Use Disclaimer Certain information contained in this presentation and statements made orally during Although
Verrica Pharmaceuticals recently provided an overview that highlights the company's focus on dermatology therapeutics, particularly its recently approved product, YCANTH. The presentation discusses various risks associated with forward-looking statements and emphasizes the reliance on both clinical trials and third-party data. With ongoing development of multiple product candidates, Verrica is positioning itself to address significant unmet dermatological needs. However, uncertainties in the drug approval process remain a critical consideration for potential investors.
Read more →VRCAVerrica Pharmaceuticals Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
Verrica Pharmaceuticals has announced that the last patient has been dosed in Part 2 of its Phase 2 clinical trial of VP-315, an oncolytic peptide aimed at treating basal cell carcinoma. This follows a significant need for new treatment options for this common form of skin cancer, with millions diagnosed annually in the U.S. The trial is a multicenter study assessing safety and efficacy, with results expected to be shared in Q2 2024. VP-315 represents a novel, non-surgical treatment approach, which aims to stimulate the immune system to combat cancer cells.
Read more →VRCAVerrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH™ for the Treatment of Common Warts
Verrica Pharmaceuticals has received the minutes from its recent Type C meeting with the FDA regarding the clinically significant development of YCANTH for treating common warts. The company considers this meeting to be highly productive and beneficial in aligning with the FDA on a pivotal Phase 3 study, aimed at expanding the drug's indication. With encouraging results from previous studies, Verrica is optimistic about YCANTH's potential market due to a lack of existing FDA-approved treatments for common warts.
Read more →VRCAVerrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
Verrica Pharmaceuticals has announced a partnership with Walgreens to distribute its FDA-approved therapy, YCANTH, for molluscum contagiosum. This collaboration will expand Verrica's distribution network beyond its current partner, Nufactor. The partnership aims to improve access to YCANTH for adults and children affected by this viral skin disease, which impacts approximately 6 million individuals in the U.S. The CEO of Verrica emphasized the importance of addressing this unmet medical need in dermatology.
Read more →VRCA▲ +62%on this news
Verrica Pharmaceuticals’ Development and Commercialization Partner, Torii Pharmaceutical Co., Ltd., Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208 for the Treatment of Molluscum Contagiosum in Japan
Verrica Pharmaceuticals announced that its partner, Torii Pharmaceutical Co., Ltd., has reported positive top-line results from a confirmatory Phase 3 trial of TO-208 for molluscum contagiosum in Japan. The trial demonstrated statistically significant efficacy compared to placebo, with patients experiencing complete clearance of lesions. The study confirmed TO-208's safety profile as well. Following these results, Torii plans to submit a manufacturing and marketing application based on the trial outcomes.
Read more →VRCAVerrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London
Verrica Pharmaceuticals, based in West Chester, PA, has announced that its President and CEO, Ted White, will present at the Jefferies Global Healthcare Conference in London from November 14-16, 2023. This event marks an opportunity for the company to showcase its advancements in dermatological therapeutics, particularly following the recent FDA approval of its lead product, YCANTH. The company is also engaged in the development of additional treatments for skin diseases, enhancing its position in the dermatology sector.
Read more →VRCA▼ -9.8%on this newsshared move
Verrica Pharmaceuticals Reports Third Quarter 2023 Financial Results Strong awareness and interest in prescribing YCANTH among dermatologists and pediatricians Over 112 million lives covered to date on commercial insuran
Verrica Pharmaceuticals has reported its financial results for the third quarter of 2023, highlighting a significant progress in commercial operations following the FDA approval of YCANTH for molluscum treatment. The company noted strong interest from dermatologists and pediatricians, with over 112 million lives now covered by insurance plans for the drug. Despite generating $2.8 million in product revenue from its first commercial sale, Verrica reported a net loss of $24.8 million during the quarter, reflecting high operating expenses. Furthermore, the company presented encouraging results from a Phase 2 trial of its oncolytic peptide, VP-315, for basal cell carcinoma treatment.
Read more →VRCAVerrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023
Verrica Pharmaceuticals Inc. has announced a conference call and webcast for November 9, 2023, to discuss its third quarter financial results and provide a corporate update. This upcoming event will showcase the company's commitment to transparency in its financial performance. Verrica is notable for its recently FDA-approved product, YCANTH™, for treating molluscum contagiosum, a common skin infection. The company is also advancing other product candidates aimed at various dermatological conditions.
Read more →VRCAVerrica Pharmaceuticals to Host Virtual KOL Event Discussing the Approval of YCANTH™ (Cantharidin) Topical Solution for the Treatment of Molluscum on October 11, 2023
Verrica Pharmaceuticals announced it will host a virtual Key Opinion Leader (KOL) event regarding the recently FDA-approved YCANTH (cantharidin) topical solution for treating molluscum contagiosum on October 11, 2023. The event will feature prominent dermatology experts who will discuss the drug's importance in addressing the medical needs of approximately six million patients, primarily children, affected by this highly contagious viral skin disease. YCANTH is the only FDA-approved treatment available for both adults and pediatric patients aged two years and older.
Read more →VRCAVerrica Pharmaceuticals Announces Participation in the H.C. Wainwright 25th Annual Global Investment Conference
Verrica Pharmaceuticals announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference on September 12, 2023. Ted White, the company's President and CEO, will engage in a fireside chat, and the company will conduct one-on-one meetings with investors. This engagement comes following the recent FDA approval of Verrica's lead product, YCANTH™, which treats molluscum contagiosum. The company is also focused on further developing additional dermatological therapies.
Read more →VRCAVerrica Pharmaceuticals Announces First Sale of YCANTH™ to FFF Enterprises
Verrica Pharmaceuticals has announced the successful first sale of YCANTH™, the first FDA-approved treatment for molluscum contagiosum, to its exclusive distributor, FFF Enterprises. This milestone marks an important step in the launch of YCANTH™, aimed at addressing the needs of approximately 6 million people affected by the disease in the U.S., primarily children. The partnership is expected to enhance the product's introduction into the U.S. dermatology and pediatric communities. Further updates on the launch progress are anticipated in November.
Read more →VRCAVerrica Issues Statement in Support of FDA’s Warning Letters to Manufacturers and Retailers for Producing and Selling Unapproved Products for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals has issued a statement in support of the FDA's recent measures against unapproved products for the treatment of molluscum contagiosum. This infraction concerns companies producing untested therapies for the viral skin infection affecting around 6 million people in the U.S. annually. The company's product, YCANTH, is the only FDA-approved treatment for this condition, anticipated to be commercially available by September 2023. Verrica emphasizes the importance of approved medical interventions, having conducted rigorous clinical trials to ensure the efficacy and safety of YCANTH.
Read more →VRCAVerrica Pharmaceuticals Announces Presentation of Lesion Clearance Data from an Ongoing Phase 2 Study of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology (AAD) 2023 Innovation Academy Meeting
Verrica Pharmaceuticals has announced the presentation of promising lesion clearance data from an ongoing Phase 2 study of VP-315, an investigational non-surgical treatment for basal cell carcinoma (BCC), at the 2023 American Academy of Dermatology Innovation Academy. The study showed that 67% of subjects achieved complete clinical and histological clearance of lesions. Insights from this study indicate a potential new treatment avenue for patients who are poor surgical candidates. The company's ongoing commitment to advancing VP-315 has led to an expansion of the study to include more clinical sites and participants.
Read more →VRCAVerrica Pharmaceuticals Reports Second Quarter 2023 Financial Results In July, FDA approved YCANTH for the treatment of molluscum, a highly contagious viral skin infection affecting approximately 6 million people annuall
Verrica Pharmaceuticals reported positive financial results for Q2 2023, highlighting the FDA's approval of YCANTH for molluscum. The drug is set to launch in September 2023 and addresses an underserved patient population of approximately 6 million. The company has secured a $125 million debt facility to support this launch and has extended its cash runway into early 2025. Additionally, Verrica is expanding enrollment for its Phase 2 trial of VP-315 to accelerate development in basal cell carcinoma.
Read more →VRCAVerrica Pharmaceuticals Announces Acceptance of Abstract Featuring Clinical Data of VP-315 for the Treatment of Basal Cell Carcinoma at the American Academy of Dermatology Association’s (AAD) 2023 Innovation Academy Meeting
Verrica Pharmaceuticals announced that an abstract featuring clinical data from its Phase 2 study of VP-315 for basal cell carcinoma has been accepted for presentation at the 2023 American Academy of Dermatology Innovation Academy. The study evaluates the non-surgical immunotherapy's antitumor activity and aims to offer a novel treatment option for BCC. The ongoing trial will involve around 80 adults with biopsy-proven cases of the disease. The company holds an exclusive license for VP-315's development and commercialization, focusing on various skin cancer indications.
Read more →VRCADisclaimer Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources
Verrica Pharmaceuticals has released a presentation discussing its FDA-approved product, YCANTH, the first treatment for Molluscum Contagiosum. While the company expresses confidence in its forward-looking statements regarding future products and strategies, it emphasizes that these are not guaranteed. The presentation also points out various risk factors that may influence the company's performance and market reception. Overall, while the FDA approval is a significant milestone, uncertainties surrounding the drug development process persist.
Read more →VRCAVerrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed
Verrica Pharmaceuticals has completed a $125 million debt financing deal with OrbiMed, receiving $50 million initially and the potential for an additional $75 million based on revenue milestones. The funding will primarily support the commercialization of YCANTH™, an FDA-approved treatment for molluscum contagiosum, aimed at addressing a pressing healthcare need in dermatology. The loan, maturing in July 2028, carries a variable interest rate that includes a SOFR floor, which may impact financial planning. This financing is seen as a strategic move to bolster operations without diluting equity.
Read more →VRCAVerrica Pharmaceuticals Announces FDA Approval of YCANTH (cantharidin) topical solution as the First FDA approved Treatment of Pediatric and Adult Patients with Molluscum Contagiosum Molluscum, is a highly contagious vir
Verrica Pharmaceuticals has received FDA approval for YCANTH (cantharidin) topical solution, marking it as the first treatment for molluscum contagiosum in both pediatric and adult patients. The approval comes after encouraging results from two Phase 3 clinical trials that demonstrated significant lesion clearance rates. YCANTH will be commercially available by September 2023, providing a new option for patients suffering from this contagious skin infection. Despite the positive news, the treatment may cause local skin reactions in a majority of patients.
Read more →VRCAVerrica Pharmaceuticals Announces Closing of $125 Million Debt Financing with OrbiMed Verrica received $50M upon the close of the transaction; $75M of additional capital available in tranches based on the achievement of
Verrica Pharmaceuticals has completed a $125 million debt financing with OrbiMed, receiving $50 million immediately and the potential for an additional $75 million based on revenue milestones. This funding aims to support the commercialization of their FDA-approved treatment YCANTH for molluscum contagiosum, which affects millions of individuals. The financing arrangement includes a five-year term loan, maturing in July 2028, accompanied by certain operational risks related to revenue achievement.
Read more →VRCA▲ +6.6%on this news
Verrica Pharmaceuticals Announces Presentation at the Jefferies Healthcare Conference in New York
Verrica Pharmaceuticals Inc. has announced that its President and CEO, Ted White, will present at the Jefferies Healthcare Conference in New York from June 7-9, 2023. The event aims to discuss the company's developments in dermatological therapeutics, including its late-stage product candidates. Interested participants can access a live webcast of the event as well as a replay afterward, ensuring that stakeholders remain informed about the company's progress.
Read more →VRCAVerrica Pharmaceuticals Announces Presentation at the RBC Capital Markets Global Healthcare Conference
Verrica Pharmaceuticals Inc. announced that its President and CEO, Ted White, will present at the RBC Capital Markets Global Healthcare Conference on May 17, 2023. The conference will take place at the InterContinental New York Barclay Hotel and is expected to showcase Verrica's advancements in dermatology therapeutics. Notably, the company is working on several late-stage product candidates to address common skin conditions. A webcast of the presentation will be available for investors and stakeholders.
Read more →VRCAVerrica Pharmaceuticals Reports First Quarter 2023 Financial Results New Drug Application for YCANTH (VP-102) PDUFA Goal Date of
Verrica Pharmaceuticals announced its first quarter 2023 financial results, highlighting an upcoming PDUFA goal date of July 23, 2023, for YCANTH, a potential treatment for molluscum contagiosum. The company raised $32.5 million in February 2023 to bolster its cash reserves and support its developments. Additionally, the Phase 2 trial for VP-315, targeting basal cell carcinoma, progressed to Part 2 following positive assessments in initial phases. Overall, the company is optimistic about achieving significant milestones in the near future.
Read more →VRCAVerrica Pharmaceuticals Announces Dosing of the First Patient in Part 2 of Phase 2 Study Evaluating VP-315 for the Treatment of Basal Cell Carcinoma
Verrica Pharmaceuticals has announced the dosing of the first patient in Part 2 of its Phase 2 study for VP-315, aimed at treating basal cell carcinoma. This study follows positive results from Part 1, where VP-315 demonstrated a strong safety profile and evidence of clinical activity. The trial seeks to refine dosing regimens before advancing to Part 3, anticipated in the first half of 2024. VP-315 may offer an innovative non-surgical treatment for a common and often surgically treated skin cancer.
Read more →VRCAVerrica Pharmaceuticals Announces Presentation at the 22nd Annual Needham Virtual Healthcare Conference
Verrica Pharmaceuticals Inc. announced that its President and CEO, Ted White, will present at the 22nd Annual Needham Virtual Healthcare Conference from April 17 to 20, 2023. The presentation will analyze their late-stage product candidate, VP-102, aimed at treating skin conditions such as molluscum and external genital warts. This event highlights the company's ongoing efforts in advancing dermatological therapeutics and their development of additional candidates.
Read more →VRCAVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Financial Results New Drug Application for VP-102 assigned PDUFA goal date of
Verrica Pharmaceuticals announced its financial results for Q4 and FY 2022, indicating progress in its drug development pipeline. The company reported a net loss of $24.5 million for the year but has successfully raised $32.5 million to support operations into 2024. VP-102, aimed at treating molluscum contagiosum, gained FDA's acceptance for a New Drug Application resubmission, with potential benefits for millions of affected patients. Additionally, dosing of the first patient for Phase 2 trials of VP-315 for basal cell carcinoma is expected in Q2 2023.
Read more →VRCAVerrica Pharmaceuticals Announces Participation at The Cowen 43rd Annual Health Care Conference
Verrica Pharmaceuticals Inc. announced its participation in The Cowen 43rd Annual Health Care Conference, scheduled for March 6-8, 2023, in Boston, MA. Ted White, the company's President and CEO, will engage in a fireside chat during the event. The company is known for developing treatments for skin diseases, including its late-stage candidate VP-102, which targets molluscum and warts. The event offers an opportunity for company updates and discussions regarding future developments in its product pipeline.
Read more →VRCA▼ -5.5%on this newsshared move
Verrica Pharmaceuticals Announces FDA Acceptance of Filing of Resubmitted NDA for VP-102 for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals has announced that the FDA has accepted its resubmitted New Drug Application (NDA) for VP-102, a potential treatment for molluscum contagiosum. The FDA has set a Prescription Drug User Fee Act (PDUFA) goal date of July 23, 2023, for the application. VP-102 is aimed at addressing a significant unmet need in dermatological treatments, as there are currently no approved therapies for this contagious viral skin infection affecting approximately six million Americans, primarily children. The company is seeking conditional approval to market the drug under the brand name YCANTH™.
Read more →VRCA▲ +5.6%on this news
Verrica Announces Pricing of $32.5 Million Underwritten Offering of Common Stock and Pre-Funded Warrants
Verrica Pharmaceuticals Inc. has announced the pricing of its underwritten offering, aiming to raise approximately $32.5 million by selling 750,000 shares of common stock and pre-funded warrants. The shares are priced at $6.75 each, with the offering expected to close on February 23, 2023, subject to customary conditions. The offering will be led by a healthcare dedicated fund and will enhance funding for Verrica's dermatology developments.
Read more →VRCAVerrica Pharmaceuticals Announces Resubmission of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
Verrica Pharmaceuticals has resubmitted its New Drug Application for VP-102, aiming for FDA approval as the first treatment for molluscum contagiosum. The company believes it has resolved the issues that led to a Complete Response Letter, specifically around manufacturing. VP-102, a topical product combining cantharidin, is intended for a substantial patient population, mainly children, affected by this viral skin disease. The company also seeks conditional approval under the brand name YCANTH™ and has completed Phase 2 studies for other indications.
Read more →VRCA▲ +14.9%on this news· ran to +51% by day 3
Verrica Pharmaceuticals Announces the Successful Technology Transfer of Bulk Solution Manufacturing of VP-102 to Piramal Pharma Solutions
Verrica Pharmaceuticals has successfully completed the technology transfer of bulk solution manufacturing of its lead product candidate, VP-102, to Piramal Pharma Solutions. This milestone includes the completion of the registration stability batch and the manufacture of three process validation batches. The company is preparing for a resubmission of its NDA for VP-102, which targets the treatment of molluscum contagiosum, with expectations set for the first quarter of 2023. This progress is seen as a significant step towards regulatory approval and marketing of the product in the U.S.
Read more →VRCAVerrica Pharmaceuticals Reports Third Quarter 2022 Financial Results Reiterates expectation to resubmit NDA for VP-102 for Molluscum Contagiosum in Q1 2023 Part 1 of Phase 2 for VP-LTX-315 for Basal Cell Carcinoma on tra
Verrica Pharmaceuticals Reports Third Quarter 2022 Financial Results Reiterates expectation to resubmit NDA for VP-102 for Molluscum Contagiosum in Q1 2023 Part 1 of Phase 2 for VP-LTX-315 for Basal Cell Carcinoma on track to conclude Q1 2023 WEST CHESTER, PA November 7, 2022
Read more →VRCA▲ +8.9%on this news
Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright 24th Annual Global Investment Conference
WEST CHESTER, Pa., Aug. 31, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, wi
Read more →VRCA▲ +5.2%on this news· ran to +17% by day 1
Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the NDA for VP-102 for the treatmen
Verrica Pharmaceuticals Reports Second Quarter 2022 Financial Results Verrica held Type A meeting with the FDA regarding the path forward for the resubmission and potential approval of the NDA for VP-102 for the treatment of molluscum contagiosum Verrica has begun working with
Read more →VRCA▼ -6.3%on this news
Verrica Pharmaceuticals Announces Start of Phase 3 Trial of VP-102 for the Treatment of Molluscum Contagiosum by Torii Pharmaceutical Co., Ltd. in Japan
The Company earns $8 Million Phase 3 Milestone Payment WEST CHESTER, Pa., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today
Read more →VRCA▼ -6.3%on this news
Verrica Pharmaceuticals Inc. Investors: Class action lawsuit filed on behalf of investors; Deadline August 5, 2022; the Portnoy Law Firm
Investors with Losses of $100,000 can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, July 31, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) investors that a class action filed on behalf
Read more →VRCA▼ -11.5%on this news· ran to +26% by day 3
Verrica Announces Pricing of Public Offering of Common Stock
WEST CHESTER, Pa., June 29, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced the pricing of its underwritten public offering
Read more →VRCA▼ -6.9%on this news· ran to -18% by day 1shared move
Verrica Announces Proposed Public Offering of Common Stock West Chester, Pa.
Verrica Announces Proposed Public Offering of Common Stock West Chester, Pa., June 29, 2022 (GLOBE NEWSWIRE) Verrica Pharmaceuticals Inc. (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced
Read more →VRCA▲ +6.9%on this newsshared move
Verrica Pharmaceuticals Holds Type A Meeting with FDA for VP-102 for Molluscum Contagiosum
WEST CHESTER, Pa., June 28, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Company held a Type A meeting with the
Read more →VRCAVerrica Pharmaceuticals Inc. Investors: Company Investigated by the Portnoy Law Firm
Investors can contact the law firm at no cost to learn more about recovering their losses LOS ANGELES, June 27, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Verrica Pharmaceuticals Inc. (NASDAQ: VRCA) investors that the firm has initiated an investigation into possible
Read more →VRCAVERRICA PHARMACEUTICALS INC. CLASS ACTION ALERT: Wolf Haldenstein Adler Freeman & Herz LLP announces that a securities class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania against Verrica Pharmaceuticals Inc.
NEW YORK, June 14, 2022 (GLOBE NEWSWIRE) -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a federal securities class action lawsuit has been filed in the United States District Court for the Eastern District of Pennsylvania on behalf of persons and entities that purcha
Read more →VRCA▼ -63.8%on this news
Verrica Receives Complete Response Letter from the FDA for its NDA for VP-102 as a Direct Result of Deficiencies at General Reinspection of Sterling Pharmaceuticals Services, LLC
Verrica has been advised that PAI (Pre-Approval Inspection) was conducted at Sterling and is not aware of any reported observations related to the PAI of VP-102 operations Review Division had advised Verrica that the review of NDA was completed and label was ready to be communic
Read more →VRCAVerrica Pharmaceuticals Reports First Quarter 2022 Financial Results Upcoming PDUFA date of
Verrica Pharmaceuticals Reports First Quarter 2022 Financial Results Upcoming PDUFA date of May 24, 2022 for VP-102 NDA for the treatment of molluscum First patient dosed in Phase 2 trial of LTX-315 in basal cell carcinoma WEST CHESTER, PA May 9, 2022 (GLOBE NEWSWIRE) Verrica
Read more →VRCAVerrica Pharmaceuticals Announces Participation in the 21st Annual Needham Virtual Healthcare Conference
WEST CHESTER, Pa., April 07, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, w
Read more →VRCAVerrica Pharmaceuticals Announces First Patient Dosed in Phase 2 Study of LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
LTX-315’s novel mechanism of action directly targets cancerous skin cells to induce an anti-tumor immune response, providing a potential alternative to surgery There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need fo
Read more →VRCAVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results NDA for VP-102 for the treatment of molluscum assigned a PDUFA date of
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Financial Results NDA for VP-102 for the treatment of molluscum assigned a PDUFA date of May 24, 2022 Company expects to dose first patient in Phase 2 trial of LTX-315 in basal cell carcinoma in the first quarte
Read more →VRCAVerrica Pharmaceuticals Announces Participation in the 42nd Annual Cowen Virtual Healthcare Conference
WEST CHESTER, Pa., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, wi
Read more →VRCAVerrica Pharmaceuticals Announces Acceptance by FDA of NDA Resubmission for VP-102 for the Treatment of Molluscum Contagiosum
WEST CHESTER, Pa., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the U.S. Food and Drug Administration (F
Read more →VRCAVerrica Pharmaceuticals Announces FDA Acceptance of its IND Application for LTX-315, a Potential First-in-Class Oncolytic Peptide-Based Immunotherapy, for the Treatment of Basal Cell Carcinoma
Company expects to initiate Phase 2 trial in basal cell carcinoma in 1Q 2022 Non-melanoma skin cancers are the most common form of cancer in the U.S., with over 5 million diagnoses each year WEST CHESTER, Pa., Nov. 18, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Ver
Read more →VRCAVerrica Pharmaceuticals Reports Third Quarter 2021 Financial Results Contract Manufacturer identified in prior CRL receives satisfactory resolution (VAI) of the facility s identified deficiencies from the FDA Verrica is
Verrica Pharmaceuticals Reports Third Quarter 2021 Financial Results Contract Manufacturer identified in prior CRL receives satisfactory resolution (VAI) of the facility s identified deficiencies from the FDA Verrica is engaging with the FDA on next steps toward potential appr
Read more →VRCAVerrica Pharmaceuticals Receives Complete Response Letter from the FDA identifying deficiencies at a facility of a Contract Manufacturer for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
No Specific Deficiencies Related to the Manufacturing of VP-102 Identified by FDA in its General Inspection of a Facility of the Contract Manufacturer No Clinical, Safety or CMC Issues Specific to VP-102 Identified WEST CHESTER, Pa., Sept. 20, 2021 (GLOBE NEWSWIRE) -- Verrica P
Read more →VRCAVerrica Pharmaceuticals Reports Second Quarter 2021 Financial Results
Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results WEST CHESTER, PA August 10, 2021 (GLOBE NEWSWIRE) Verrica Pharmaceuticals Inc. ( Verrica ) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interve
Read more →VRCAVerrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer
Company strengthens management team in anticipation of the potential commercial launch of VP-102, if approved WEST CHESTER, Pa., July 09, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications f
Read more →VRCAVerrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum Prescription Drug User Fee Act (PDUFA) goal date extended by three months to
Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum Prescription Drug User Fee Act (PDUFA) goal date extended by three months to September 23, 2021 WEST CHESTER, PA May 28, 2021 (GLOBE NEWSWIRE) Verr
Read more →VRCAVerrica Pharmaceuticals Announces Participation in the Jefferies Virtual Healthcare Conference
WEST CHESTER, Pa., May 26, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, wil
Read more →VRCAVerrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference
WEST CHESTER, Pa., May 12, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, wil
Read more →VRCAVerrica Pharmaceuticals Reports First Quarter 2021 Financial Results Expanded commercial team in preparation for potential FDA approval of VP-102 for the treatment of molluscum, which has been assigned a PDUFA goal date
Verrica Pharmaceuticals Reports First Quarter 2021 Financial Results Expanded commercial team in preparation for potential FDA approval of VP-102 for the treatment of molluscum, which has been assigned a PDUFA goal date of June 23, 2021 Raised approximately $30 million, befor
Read more →VRCAVerrica Pharmaceuticals Announces Participation in the 20th Annual Needham Virtual Healthcare Conference
WEST CHESTER, Pa., April 06, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, w
Read more →VRCAVerrica Announces Election of Gary Goldenberg, MD, Verrica’s Chief Medical Officer, to Membership in the American Dermatological Association
WEST CHESTER, Pa., March 29, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Gary Goldenberg, M.D., Verrica’s Chief Me
Read more →VRCAVerrica Pharmaceuticals Announces Exclusive Licensing Agreement With Torii Pharmaceutical Co., Ltd. To Develop and Commercialize VP-102 For Molluscum and Common Warts in Japan
- Torii to make upfront payment of $11.5 million to Verrica in addition to other potential milestone payments of up to $58 million and, if marketed in Japan, tiered transfer price payments as a percentage of net sales - WEST CHESTER, Pa., March 17, 2021 (GLOBE NEWSWIRE) -- Verri
Read more →VRCAVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results FDA accepts resubmitted NDA for VP-102 for the treatment of molluscum contagiosum with PDUFA goal date of
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2020 Financial Results FDA accepts resubmitted NDA for VP-102 for the treatment of molluscum contagiosum with PDUFA goal date of June 23, 2021 Verrica Announces Torii Pharmaceutical Has Exercised Option to Acquire Ex
Read more →VRCAVerrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference
WEST CHESTER, Pa., March 03, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, w
Read more →VRCAVerrica Pharmaceuticals Announces Participation in the Cowen 41st Annual Health Care Conference
WEST CHESTER, Pa., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, wi
Read more →VRCAVerrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum - PDUFA goal date assigned is
Verrica Pharmaceuticals Announces FDA Filing Acceptance of Resubmitted New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum - PDUFA goal date assigned is - VP-102 (cantharidin 0.7% Topical Solution) could potentially be the first FDA-approved treatment fo
Read more →VRCAVerrica Pharmaceuticals Presents Positive Data From Clinical Studies Evaluating the Safety and Efficacy of VP-102 in Molluscum and External Genital Warts at the 2021 Winter Clinical Dermatology Conference
- In new post hoc analyses of the Phase 3 molluscum trials segmenting molluscum lesions by body region and study visit, the percentage of participants with complete clearance of all baseline and new molluscum lesions was statistically significantly higher in the VP-102 group than
Read more →VRCACompany Overview January 2021 1 Disclaimer Certain information contained in this presentation and statements made orally The information in this presentation, including without limitation the forward- during this present
Overview January 2021 1 Disclaimer Certain information contained in this presentation and statements made orally The information in this presentation, including without limitation the forward- during this presentation relates to or is based on studies, publications, surveys loo
Read more →VRCAVerrica Pharmaceuticals Announces Receipt of Final FDA Minutes Following Type A Meeting Regarding Resubmission of the NDA for VP-102 in Molluscum
WEST CHESTER, Penn., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that it has received the final meeting minu
Read more →VRCAVerrica Pharmaceuticals Announces Participation in the Jefferies Virtual London Healthcare Conference
WEST CHESTER, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, wi
Read more →VRCAVerrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts (CARE-1) - 35% of subjects treated with VP-102 achieved complete clearance of all tre
Verrica Pharmaceuticals Announces Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with External Genital Warts (CARE-1) 35% of subjects treated with VP-102 achieved complete clearance of all treatable genital warts vs 2.4% for vehicle (p=0.0001) - - VP-1
Read more →VRCAVerrica Pharmaceuticals Reports Third Quarter 2020 Financial Results - Verrica completes Type A meeting and expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2
Verrica Pharmaceuticals Reports Third Quarter 2020 Financial Results - Verrica completes Type A meeting and expects to resubmit its New Drug Application for VP-102 for the treatment of molluscum in the first quarter of 2021 - WEST CHESTER, PA Nov. 9, 2020 (GLOBE NEWSWIRE) Verr
Read more →VRCAVerrica Pharmaceuticals Announces Participation in the H.C. Wainwright 22nd Annual Global Investment Conference
WEST CHESTER, Pa., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CEO, w
Read more →VRCACompany Overview September 2020 Copyright 2020 Verrica Pharmaceuticals. All rights reserved. DISCLAIMER Certain information contained in this presentation and statements made orally during The information in this present
DISCLAIMER Certain information contained in this presentation and statements made orally during The information in this presentation, including without limitation the forward-looking this presentation relates to or is based on studies, publications, surveys and other data statem
Read more →VRCAVerrica Pharmaceuticals Licenses LTX-315, A First-in-Class Oncolytic Peptide Based Immunotherapy, from Lytix Biopharma AS, for the Treatment of Dermatologic Oncology Indications
WEST CHESTER, Pa., Aug. 11, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (NASDAQ: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced that the Company has entered into an exclusiv
Read more →VRCAVerrica Pharmaceuticals Announces Option Agreement with Torii Pharmaceutical to Develop & Commercialize VP-102 in Japan
WEST CHESTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced it has entered into an Option Agreement
Read more →VRCAVerrica Pharmaceuticals Reports Second Quarter 2020 Financial Results - Company intends to request a Type A meeting with FDA during the third quarter of 2020 to discuss next steps for resubmission of an NDA for VP-102 fo
Verrica Pharmaceuticals Reports Second Quarter 2020 Financial Results - Company intends to request a Type A meeting with FDA during the third quarter of 2020 to discuss next steps for resubmission of an NDA for VP-102 following Complete Response Letter - - Key leadership addit
Read more →VRCAVerrica Pharmaceuticals Announces Dr. Lawrence Eichenfield Joins Board of Directors
– Leading pediatric dermatologist brings significant expertise in the treatment of skin diseases to help inform development of the Company’s product candidates – WEST CHESTER, Pa., July 23, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a derma
Read more →VRCAVerrica Pharmaceuticals Announces Clinical and Drug Development Leadership Changes Dr. Gary Goldenberg appointed Chief Medical Officer; Dr. Brad Catalone assumes the role of Head of Drug Development New leadership streng
Verrica Pharmaceuticals Announces Clinical and Drug Development Leadership Changes Dr. Gary Goldenberg appointed Chief Medical Officer; Dr. Brad Catalone assumes the role of Head of Drug Development New leadership strengthens expertise in Clinical, Chemistry, Manufacturing, an
Read more →VRCAVerrica Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum Complete Response Letter Requests Additional Chemistry, Manufactur
Verrica Pharmaceuticals Receives Complete Response Letter from the FDA for its New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum Complete Response Letter Requests Additional Chemistry, Manufacturing, and Controls (CMC) and Human Factors Information No
Read more →VRCAVerrica Pharmaceuticals Provides Regulatory Update on VP-102
Verrica Pharmaceuticals Provides Regulatory Update on VP-102 WEST CHESTER, Pa., June 29, 2020 (GLOBE NEWSWIRE) Verrica Pharmaceuticals Inc. ( Verrica ) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventi
Read more →VRCAVerrica Pharmaceuticals Announces Positive Results from Two New Pooled Analyses of the Phase 3 CAMP Trials of VP-102 in Molluscum Contagiosum
- Pre-specified exploratory analysis showed VP-102 brought about a statistically significant percentage of patients with complete molluscum lesion clearance across all lesion count quartiles compared to vehicle - - Additional post-hoc analysis showed any patient with baseline ch
Read more →VRCAVerrica Pharmaceuticals Appoints Diem Nguyen, Ph.D., M.B.A., to its Board of Directors Global biopharmaceutical industry veteran brings significant commercial expertise and business acumen to help advance the Company s m
Verrica Pharmaceuticals Appoints Diem Nguyen, Ph.D., M.B.A., to its Board of Directors Global biopharmaceutical industry veteran brings significant commercial expertise and business acumen to help advance the Company s medical dermatology portfolio WEST CHESTER, PA June 10, 20
Read more →VRCAVerrica Pharmaceuticals to Present at the Jefferies 2020 Healthcare Conference
WEST CHESTER, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CE
Read more →VRCAVerrica Pharmaceuticals Reports First Quarter 2020 Financial Results - Secured $55 million in non-dilutive loan facilities, of which $35 million was borrowed upon closing - - Continued to prepare for potential U.S. appro
Verrica Pharmaceuticals Reports First Quarter 2020 Financial Results - Secured $55 million in non-dilutive loan facilities, of which $35 million was borrowed - Continued to prepare for potential U.S. approval of VP-102 for the treatment of molluscum contagiosum - - Issuance o
Read more →VRCAVerrica Pharmaceuticals to Present at the Bank of America Merrill Lynch Global Healthcare Conference and the RBC Capital Markets Global Healthcare Conference
WEST CHESTER, Pa., May 06, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that Ted White, Verrica President and CE
Read more →VRCACertain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica
April 2020 Company Overview Copyright Certain information contained in this presentation and statements made orally during this presentation relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Verrica's own internal esti
Read more →VRCAVerrica Pharmaceuticals to Participate in the 19th Annual Needham Virtual Healthcare Conference
WEST CHESTER, Pa., April 09, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that Ted White, Verrica President and
Read more →VRCAVerrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results - New Drug Application for VP-102 for the treatment of molluscum contagiosum was accepted for filing by the U.S. Food and Drug Administr
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results - New Drug Application for VP-102 for the treatment of molluscum contagiosum was accepted for filing by the U.S. Food and Drug Administration; assigned PDUFA goal date is July 13, 2020 - - Rece
Read more →VRCAVerrica Pharmaceuticals Secures $55 Million in Loan Facilities Led by Silicon Valley Bank
WEST CHESTER, Pa., March 11, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that it has entered into a mezzanine l
Read more →VRCAVerrica Pharmaceuticals to Attend Several Upcoming Investor Conferences
WEST CHESTER, Pa., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases requiring medical interventions, today announced that Ted White, Verrica President and C
Read more →VRCAVerrica Pharmaceuticals Announces the Hiring of Two Vice Presidents to Further Grow its Commercial Capabilities
– Gerard DiGirolamo joins as Vice President, Sales, and Sheila Kennedy joins as Vice President, Marketing – – Extensive expertise and deep relationships in dermatology therapeutics will support potential launch of YCANTH™ for the treatment of molluscum contagiosum – WEST CHES
Read more →VRCAVerrica Pharmaceuticals Announces Presentation of Positive Data from New Pooled Analysis of Phase 3 CAMP Trials of VP-102
- Analysis suggested statistically significantly higher lesion clearance with VP-102 compared to vehicle in all regions of the body, including those deemed most sensitive - - If approved, VP-102 will be marketed in the United States as YCANTH™ (cantharidin 0.7% Topical Solution)
Read more →VRCAVerrica Pharmaceuticals Announces FDA Filing Acceptance of New Drug Application for VP-102 for the Treatment of Molluscum Contagiosum
- PDUFA date assigned is July 13, 2020 - - VP-102 (cantharidin 0.7% Topical Solution) could potentially be the first FDA-approved treatment for molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primaril
Read more →VRCAVerrica Pharmaceuticals Announces Participation in the Piper Jaffray 31st Annual Healthcare Conference
WEST CHESTER, Pa., Nov. 25, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases,
Read more →VRCAVerrica Pharmaceuticals Announces Passing of Board of Directors Member Glenn Oclassen
WEST CHESTER, Pa., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), announces with deep sadness the passing of Glenn Oclassen, a valued member of the Company’s Board of Directors. Mr. Oclassen passed away on November 13, 2019. “Glenn was
Read more →VRCAVerrica Pharmaceuticals Reports Third Quarter 2019 Financial Results -Submitted New Drug Application to U.S. Food and Drug Administration for VP-102 for the treatment of molluscum contagiosum -Presented three abstracts a
Verrica Pharmaceuticals Reports Third Quarter 2019 Financial Results -Submitted New Drug Application to U.S. Food and Drug Administration for VP-102 for the treatment of molluscum contagiosum -Presented three abstracts at the Fall Clinical Dermatology Conference, including two
Read more →VRCAVerrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39 th Annual Fall Clinical Dermatology Conference Pooled analyses of the Phase 3 CAMP studies in molluscum contag
Verrica Pharmaceuticals Announces Presentation of Positive Data from Clinical Trials of VP-102 at the 2019 39th Annual Fall Clinical Dermatology Conference WEST CHESTER, Pa., Oct. 18, 2019 (GLOBE NEWSWIRE) Verrica Pharmaceuticals Inc. ( Verrica ) (Nasdaq: VRCA), a medical der
Read more →VRCAVerrica Pharmaceuticals Appoints Eugene Scavola to the Position of Executive Vice President, Technical Operations
WEST CHESTER, Pa., Oct. 09, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases,
Read more →VRCAVerrica Pharmaceuticals Announces Leadership Team Update
WEST CHESTER, Pa., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases,
Read more →VRCAVerrica Pharmaceuticals Submits New Drug Application to U.S. Food and Drug Administration for VP-102 for the Treatment of Molluscum Contagiosum
WEST CHESTER, Pa., Sept. 16, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases
Read more →VRCAVerrica Pharmaceuticals Announces Participation in the H.C. Wainwright 21st Annual Global Investment Conference
WEST CHESTER, Pa., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases,
Read more →VRCAVerrica Pharmaceuticals Reports Second Quarter 2019 Financial Results -Achieved positive topline results from Phase 2 clinical trial of VP-102 in patients with common warts -Enrolled first patient in a Phase 2 trial of V
Verrica Pharmaceuticals Reports Second Quarter 2019 -Achieved positive topline results from Phase 2 clinical trial of VP-102 in patients with common -Enrolled first patient in a Phase 2 trial of VP-102 for the treatment of external genital warts -NDA for molluscum contagiosum
Read more →VRCAVerrica Pharmaceuticals Enrolls First Patient in Phase 2 Trial of VP-102 for the Treatment of External Genital Warts
WEST CHESTER, Pa., June 27, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases, t
Read more →VRCAVerrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts 51% of subjects in Cohort 2 achieved complete clearance of all treatable warts VP-102 was well-t
Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts 51% of subjects in Cohort 2 achieved complete clearance of all treatable warts VP-102 was well-tolerated with no serious adverse events reported Common
Read more →VRCAVerrica Pharmaceuticals Announces Participation in the Jefferies 2019 Healthcare Conference
WEST CHESTER, Pa., May 21, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases,
Read more →VRCAVerrica Pharmaceuticals Reports First Quarter 2019 Financial Results -Reported positive topline data from pivotal Phase 3 clinical trials of VP-102 for the treatment of molluscum contagiosum -Preparing to submit NDA in s
Verrica Pharmaceuticals Reports First Quarter 2019 -Reported positive topline data from pivotal Phase 3 clinical trials of VP-102 for the treatment of molluscum contagiosum -Preparing to submit NDA in second half of 2019 WEST CHESTER, PA May 7, 2019 (GLOBE NEWSWIRE) Verrica P
Read more →VRCAVerrica Pharmaceuticals Announces Participation in Upcoming Investor Conferences
WEST CHESTER, Pa., May 01, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that provide meaningful benefit for people living with skin diseases,
Read more →VRCAVerrica Reports Fourth Quarter and Full Year 2018 Financial Results
Verrica Reports Fourth Quarter and Full Year 2018 Financial Results WEST CHESTER, PA March 7, 2019 (GLOBE NEWSWIRE) Verrica Pharmaceuticals Inc. ( Verrica ) (Nasdaq: VRCA), a medical dermatology company committed to the development and commercialization of novel treatments that
Read more →VRCAVerrica Pharmaceuticals Presents Positive Results from Two Phase 3 Clinical Trials of VP-102 in Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Meeting
– CAMP-1 and CAMP-2 trials of VP-102 for the treatment of molluscum contagiosum successfully met their primary endpoints – – Molluscum contagiosum is a highly contagious, significantly undertreated viral skin disease that affects approximately six million people in the U.S., man
Read more →VRCAVerrica Pharmaceuticals Announces Participation in the Cowen and Company 39th Annual Healthcare Conference
WEST CHESTER, Pa., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet
Read more →VRCAVerrica Announces Late-Breaking Oral Presentation at the 2019 American Academy of Dermatology Annual Meeting
WEST CHESTER, Pa., Feb. 12, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on the development of innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today announced t
Read more →VRCAVerrica Appoints Neil D. DeHenes as Vice President of Distribution, Trade and Channel Strategy
WEST CHESTER, Pa., Jan. 07, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unm
Read more →VRCAVerrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum Contagiosum CAMP-1 and CAMP-2 Phase 3 pivotal trials for molluscum contagiosum both achieve statisti
Verrica Achieves Positive Topline Results from Two Pivotal Phase 3 Clinical Trials of VP-102 in Patients with Molluscum Contagiosum CAMP-1 and CAMP-2 Phase 3 pivotal trials for molluscum contagiosum both achieve statistical significance for the primary endpoint with p-values
Read more →VRCAVerrica Pharmaceuticals Reports Third Quarter 2018 Financial Results
Verrica Pharmaceuticals Reports Third Quarter 2018 Financial Results WEST CHESTER, PA November 7, 2018 (GLOBE NEWSWIRE) Verrica Pharmaceuticals Inc. ( Verrica ) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceut
Read more →VRCAVerrica Pharmaceuticals Announces Participation in the Jefferies 2018 London Healthcare Conference
WEST CHESTER, Pa., Nov. 01, 2018 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet
Read more →VRCAVerrica Pharmaceuticals Inc. Announces Inclusion in Russell 2000 and Russell 3000 Indexes
WEST CHESTER, Pa., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unme
Read more →VRCAVerrica Announces Successful Phase 2 Innovate Trial and Complete Enrollment of Phase 3 Trials of VP-102 in Molluscum Contagiosum Ahead of Schedule Innovate trial results reaffirm Phase 3 protocol design No serious advers
Verrica Announces Successful Phase 2 Innovate Trial and Complete Enrollment of Phase 3 Trials of VP-102 in Molluscum Contagiosum Ahead of Schedule Innovate trial results reaffirm Phase 3 No serious adverse events (SAEs) reported during the Innovate trial Phase 3 pivotal trials
Read more →VRCAVerrica Appoints Neetu Dhaliwal as Vice President of Business Development
WEST CHESTER, Pa., Aug. 15, 2018 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unm
Read more →VRCAVerrica Reports Second Quarter 2018 Financial Results
Verrica Reports Second Quarter 2018 Financial Results WEST CHESTER, PA August 7, 2018 (GLOBE NEWSWIRE) Verrica Pharmaceuticals Inc. ( Verrica ) (Nasdaq: VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for
Read more →VRCAVerrica Pharmaceuticals Inc. Announces Closing of Initial Public Offering
WEST CHESTER, Pa., June 19, 2018 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq:VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unme
Read more →VRCAVerrica Pharmaceuticals Inc. Announces Pricing of Initial Public Offering
WEST CHESTER, Pa., June 14, 2018 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq:VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unme
Read more →Competitive Position
How VRCA ranks across every disease it competes inCompetitive Position is a premium feature
See how VRCA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial